S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)

Zoetis (ZTS) Stock Price, News & Analysis

$146.05
-7.06 (-4.61%)
(As of 03:15 PM ET)
Today's Range
$145.80
$151.54
50-Day Range
$149.81
$199.94
52-Week Range
$145.80
$201.92
Volume
4.42 million shs
Average Volume
3.01 million shs
Market Capitalization
$66.80 billion
P/E Ratio
28.81
Dividend Yield
1.18%
Price Target
$221.75

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
49.1% Upside
$221.75 Price Target
Short Interest
Healthy
0.80% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.15mentions of Zoetis in the last 14 days
Based on 48 Articles This Week
Insider Trading
Selling Shares
$371,293 Sold Last Quarter
Proj. Earnings Growth
10.36%
From $5.79 to $6.39 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.78 out of 5 stars

Medical Sector

44th out of 918 stocks

Pharmaceutical Preparations Industry

14th out of 424 stocks

ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

We Think Zoetis (NYSE:ZTS) Can Stay On Top Of Its Debt
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
Zoetis (ZTS) Fell on Slower Veterinary Visits
Zoetis Inc's Dividend Analysis
Zoetis (NYSE:ZTS) Receives Overweight Rating from Piper Sandler
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
Zoetis (ZTS) Stock Moves -0.14%: What You Should Know
Zoetis (NYSE:ZTS) Shares Down 7.8%
Zoetis (NYSE:ZTS) Hits New 52-Week Low at $148.71
Zoetis Becomes Oversold
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/1 Dividend
1/18/2024
Last Earnings
2/13/2024
Dividend Payable
3/01/2024
Ex-Dividend for 6/4 Dividend
4/18/2024
Today
4/19/2024
Next Earnings (Confirmed)
5/02/2024
Dividend Payable
6/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
98978V10
Employees
14,100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$221.75
High Stock Price Target
$260.00
Low Stock Price Target
$195.00
Potential Upside/Downside
+44.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
34.36%

Debt

Sales & Book Value

Annual Sales
$8.54 billion
Cash Flow
$6.43 per share
Book Value
$10.87 per share

Miscellaneous

Free Float
456,810,000
Market Cap
$70.03 billion
Optionable
Optionable
Beta
0.85

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products, catering to a wide range of animals from livestock to companion animals. This diversified product portfolio can provide stability and growth opportunities.
  • The company collaborates with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health, showcasing a commitment to innovation and addressing emerging needs in the industry.
  • Zoetis Inc. offers a variety of products and services in biodevices, genetic tests, and precision animal health, indicating a focus on cutting-edge technologies that could drive future revenue growth.
  • With a strong market presence and a history dating back to 1952, Zoetis Inc. has established itself as a reputable player in the animal health industry, instilling confidence in investors.
  • Considering the current stock price and recent performance trends, Zoetis Inc. shows potential for capital appreciation, making it an attractive investment option for growth-oriented investors.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • While Zoetis Inc. operates in the pharmaceutical preparations industry, which can be lucrative, it also faces regulatory challenges and competition that may impact its market position and profitability.
  • The animal health industry is subject to economic cycles and external factors, such as disease outbreaks or changes in consumer preferences, which could affect Zoetis Inc.'s financial performance and stock value.
  • Investing in Zoetis Inc. involves exposure to risks associated with research and development of new products, including uncertainties in product efficacy, regulatory approvals, and market acceptance, which could lead to financial setbacks.
  • As a publicly traded company, Zoetis Inc. is susceptible to market volatility and investor sentiment, which may result in fluctuations in its stock price and potential losses for shareholders.
  • Investors should carefully assess their risk tolerance and investment objectives before considering Zoetis Inc. as an investment, as the company's performance may not always align with market expectations or macroeconomic conditions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price target for 2024?

7 brokerages have issued twelve-month target prices for Zoetis' shares. Their ZTS share price targets range from $195.00 to $260.00. On average, they anticipate the company's share price to reach $221.75 in the next year. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2024?

Zoetis' stock was trading at $197.37 on January 1st, 2024. Since then, ZTS shares have decreased by 24.6% and is now trading at $148.74.
View the best growth stocks for 2024 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZTS earnings forecast
.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings data on Tuesday, February, 13th. The company reported $1.24 EPS for the quarter, missing analysts' consensus estimates of $1.32 by $0.08. The business had revenue of $2.21 billion for the quarter, compared to analysts' expectations of $2.19 billion. Zoetis had a trailing twelve-month return on equity of 51.25% and a net margin of 27.43%. The business's quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 earnings per share.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Tuesday, February 6th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 annualized dividend and a dividend yield of 1.16%. The ex-dividend date is Thursday, April 18th.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.73 per share and currently has a dividend yield of 1.14%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 34.12%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 27.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 5.740-5.840 for the period, compared to the consensus earnings per share estimate of 5.980. The company issued revenue guidance of $9.1 billion-$9.2 billion, compared to the consensus revenue estimate of $9.2 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?
Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.28%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), Congress Asset Management Co. MA (0.15%), Allspring Global Investments Holdings LLC (0.10%), Los Angeles Capital Management LLC (0.08%) and Sarasin & Partners LLP (0.08%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert J Polzer, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
This page (NYSE:ZTS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners